Loading your page…
Marketing-authorisation holder · Spain
659 medicines in 2 countries, as authorisation holder, manufacturer and marketer.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
1–25 of 659
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABIK 1 MG/ML SOLUCION ORAL EFG1 mg · Solución oral | Aripiprazole | Spain | Marketed | 2016 |
| ABIK 10 MG COMPRIMIDOS BUCODISPERSABLES EFG10 mg · Comprimido bucodispersable | Aripiprazole | Spain | Marketed | 2014 |
| ABIK 10 MG COMPRIMIDOS EFG10 mg · Comprimido | Aripiprazole | Spain | Marketed | 2014 |
| ABIK 15 MG COMPRIMIDOS BUCODISPERSABLES EFG15 mg · Comprimido bucodispersable | Aripiprazole | Spain | Marketed | 2014 |
| ABIK 15 MG COMPRIMIDOS EFG15 mg · Comprimido | Aripiprazole | Spain | Marketed | 2014 |
| ABIK 30 MG COMPRIMIDOS EFG30 mg · Comprimido | Aripiprazole | Spain | Marketed | 2014 |
| ABIK 5 MG COMPRIMIDOS EFG5 mg · Comprimido | Aripiprazole | Spain | Marketed | 2014 |
| ABIRATERONA KERN PHARMA 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG500 mg · Comprimido recubierto con película | Abiraterone | Spain | Marketed | 2021 |
| ACECLOFENACO KERN PHARMA 100 MG COMPRIMIDOS RECUBIERTOS CON PELÍCULA EFG100,00 mg · Comprimido recubierto con película | Aceclofenac | Spain | Marketed | 2006 |
| ACETILCISTEINA KERN PHARMA 100 MG/ML SOLUCION INYECTABLE EFG100 mg/ml · Solución inyectable | Acetylcysteine | Spain | Marketed | 2024 |
| ACETILCISTEINA KERN PHARMA 600 mg COMPRIMIDOS EFERVESCENTES600 mg · Comprimido efervescente | Acetylcysteine | Spain | Marketed | 2006 |
| ACICLOVIR KERN PHARMA 200 mg COMPRIMIDOS DISPERSABLES EFG200 mg · Comprimido dispersable | Aciclovir | Spain | Marketed | 1999 |
| ACICLOVIR KERN PHARMA 50 mg/g CREMA EFG5 g · Crema | Aciclovir | Spain | Marketed | 1999 |
| ACICLOVIR KERN PHARMA 800 mg COMPRIMIDOS DISPERSABLES EFG800 mg · Comprimido recubierto | Aciclovir | Spain | Marketed | 1999 |
| ACIDO ACETILSALICILICO KERN PHARMA 100 MG COMPRIMIDOS GASTRORRESISTENTES EFG100,00 mg · Comprimido gastrorresistente | Acetylsalicylic acid | Spain | Marketed | 2012 |
| ACIDO ALENDRONICO SEMANAL KERN PHARMA 70 mg COMPRIMIDOS EFG91,37 mg · Comprimido | Alendronic acid | Spain | Marketed | 2007 |
| ACIDO IBANDRONICO KERN PHARMA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA EFG150 mg · Comprimido recubierto con película | Ibandronic acid | Spain | Marketed | 2011 |
| ACIDOS OMEGA 3 KERN PHARMA 1.000 MG CAPSULAS BLANDAS EFG1.000 mg · Cápsula blanda | Acidos omega esteres etilicos | Spain | Marketed | 2013 |
| ALMOTRIPTAN KERN PHARMA 12,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG12,5 mg · Comprimido recubierto con película | Almotriptan | Spain | Marketed | 2013 |
| ALOPURINOL KERN PHARMA 100 mg COMPRIMIDOS EFG100 mg · Comprimido | Allopurinol | Spain | Marketed | 2001 |
| ALOPURINOL KERN PHARMA 300 mg COMPRIMIDOS EFG300 mg · Comprimido | Allopurinol | Spain | Marketed | 2001 |
| ALPRAZOLAM KERN PHARMA 0,25 mg COMPRIMIDOS EFG0,25 mg · Comprimido | Alprazolam | Spain | Marketed | 2000 |
| ALPRAZOLAM KERN PHARMA 0,5 mg COMPRIMIDOS EFG0,5 mg · Comprimido | Alprazolam | Spain | Marketed | 2000 |
| ALPRAZOLAM KERN PHARMA 1 mg COMPRIMIDOS EFG1 mg · Comprimido | Alprazolam | Spain | Marketed | 2000 |
| ALPRAZOLAM KERN PHARMA 2 mg COMPRIMIDOS EFG2 mg · Comprimido | Alprazolam | Spain | Marketed | 2000 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 657 | 548 | 109 | CompaniesAll medicines |
| Saudi Arabia | 2 | 2 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.
